EP1687001A2 — Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
Assigned to Glaxo Group Ltd · Expires 2006-08-09 · 20y expired
What this patent protects
The invention concerns the use of compounds of formula (I), (II) and (III) which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts and solvates thereof, for the treatment of schizophrenic disorders. Schizophrenic disorders of the invention are to be i…
USPTO Abstract
The invention concerns the use of compounds of formula (I), (II) and (III) which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts and solvates thereof, for the treatment of schizophrenic disorders. Schizophrenic disorders of the invention are to be intended schizophrenia, delusional disorders, affective disorders, autism or tic disorders, schizophreniform disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders. Moreover, the invention is concerned with the use of a pyrimidine derivative known as COX-2 inhibitor in combination with a neuroleptic drug for the treatment of schizophrenic disorders such as those defined above.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.